Iterum Therapeutics
Dublin, US · Founded 2015 · Ireland corporation · 5 known investors
Find your way into Iterum Therapeutics
162 people in our graph share verified history with the Iterum Therapeutics team — schools, employers, funds. One of them is your warm intro.
David Kaufmanunlockedknows Michael W. Dunne · together at Bill & Melinda Gates Medical Research Institute (overlapped)
×11knows the team · via Pfizer Global Research and Development
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens. The company's lead product, sulopenem (ORLYNVAH), has been approved by the FDA for treating uncomplicated urinary tract infections in adult women.
Founders & leadership
Iterum Therapeutics was founded in 2015 by Michael W. Dunne and Corey N. Fishman.
MW
Michael W. DunneinCo-founderMichael W. Dunne is an infectious disease specialist with nearly two decades at Pfizer developing antibacterial, antifungal, antiviral, and HIV therapeutics, followed by roles as founder and chief medical officer at Durata Therapeutics (where he led development of dalbavancin), VP of R&D at Actavis, founder and chief scientific officer at Iterum Therapeutics (overseeing FDA approval of sulopenem), and most recently chief medical officer at the Bill & Melinda Gates Medical Research Institute. He holds an M.D. from SUNY Health Science Center at Brooklyn and completed residency and fellowship training in internal medicine, pulmonary medicine, and infectious diseases at Yale University.
CN
Corey N. FishmaninCo-founder
JM
Judith M. MatthewsExecutive
JS
Jeff SchaffnitExecutive
Board
BK
Brenton K. AhrensBoard director
RM
Ronald M. HuntBoard director
MC
Mark ChinBoard director
RH
Robert HopfnerBoard director
SM
Shahzad MalikBoard director
PJ
DI
David I. KellyBoard director
PR
Paul R. EdickBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$131.4M disclosed across 4 rounds · 2015–2020
▶$2.8MraisedJul 2020 · 8 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedJul 2020 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Shahzad MalikDirector
- David KellyDirector
- Judith M. MatthewsExecutive Officer
- Michael DunneExecutive Officer
- Mark ChinDirector
- Louise BarrettExecutive Officer
- Brenton K. AhrensDirector
- Patrick J. HeronDirector
- Corey N. FishmanExecutive Officer, Director
- Ronald M. HuntDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- Sales commissions
- $350K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jul 2020
- Incorporated
- Corporation, Ireland, 2015
- Federal exemptions
- 06b
▶$2.8MraisedJun 2020 · 8 investors · PharmaceuticalsRule 506(b)
▶$2.8MraisedJun 2020 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael DunneExecutive Officer
- Patrick J. HeronDirector
- Judith M. MatthewsExecutive Officer
- Brenton K. AhrensDirector
- Mark ChinDirector
- Ronald M. HuntDirector
- Shahzad MalikDirector
- Corey N. FishmanExecutive Officer, Director
- David KellyDirector
- Louise BarrettExecutive Officer
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- Sales commissions
- $350K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Jun 2020
- Incorporated
- Corporation, Ireland, 2015
- Federal exemptions
- 06b
▶$78.1MraisedMar 2018 · 17 investors · BiotechnologyRule 506(b)
▶$78.1MraisedMar 2018 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brenton K. AhrensDirector
- Michael W. DunneExecutive Officer, Promoter
- Ronald M. HuntDirector
- Mark ChinDirector
- Corey N. FishmanExecutive Officer, Director, Promoter
- Robert HopfnerDirector
- Judith M. MatthewsExecutive Officer, Promoter
- Shahzad MalikDirector
- Jeff SchaffnitExecutive Officer
- Patrick J. HeronDirector
- David I. KellyDirector
- Paul R. EdickDirector
- James I. HealyDirector
- Offering amount
- $78.1M
- Amount sold
- $78.1M
- First sale
- May 2017
- Incorporated
- Other, Ireland, 2015
- Federal exemptions
- 06b
▶$47.6MraisedDec 2016 · 13 investors · BiotechnologyRule 506(b)
▶$47.6MraisedDec 2016 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Corey N. FishmanExecutive Officer, Director, Promoter
- Patrick J. HeronDirector
- Judith M. MatthewsExecutive Officer, Promoter
- Ronald M. HuntDirector
- James I. HealyDirector
- Brenton K. AhrensDirector
- Michael W. DunneExecutive Officer, Promoter
- David I. KellyDirector
- Paul R. EdickDirector
- Offering amount
- $47.6M
- Amount sold
- $47.6M
- First sale
- Nov 2015
- Incorporated
- Other, Ireland, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Simply Wall St31 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Robinhood29 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Public26 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
StockTwits25 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Seeking Alpha25 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Iterum Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Iterum Therapeutics do?
- Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens. The company's lead product, sulopenem (ORLYNVAH), has been approved by the FDA for treating uncomplicated urinary tract infections in adult women.
- Who founded Iterum Therapeutics?
- Iterum Therapeutics was founded by Michael W. Dunne, Corey N. Fishman in 2015.
- Who are Iterum Therapeutics's investors?
- Iterum Therapeutics's investors include Bay City Capital, Canaan Partners, Sofinnova Ventures, Frazier Life Sciences, Sofinnova Venture Partners.
- How much funding has Iterum Therapeutics raised?
- Iterum Therapeutics has disclosed $131.4M raised across 4 rounds.
- Where is Iterum Therapeutics headquartered?
- Iterum Therapeutics is headquartered in Dublin, US.